Im
Imago (Merck)
San Francisco CAFounded 201570 employees
Private CapbiotechAcquiredHematology
Platform: LSD1 MF
Market Cap
N/A
All Drugs
3
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Suramavacamten | IMA-4310 | Phase 3 | 2 | WEE1 | IPFSCLC | ||
| Tixazanubrutinib | IMA-1643 | Phase 1 | 2 | FGFR | NASH | ||
| Zorilucimab | IMA-374 | NDA/BLA | 2 | PSMA | TTR AmyloidosisCF |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)